www.deltacure2026.com

Chairs:
Pietro Lampertico
and Heiner Wedemeyer

DeltaCure

5th International **Meeting**

ACCEPTED ABSTRACTS

OCTOBER 15-16 2026 MILAN, ITALY

ORAL PRESENTATIONS

EPIDEMIOLOGY, VIROLOGY AND IMMUNOLOGY

Global and Local Epidemiology

17 **High prevalence of HDV and HBV detected amongst household contacts of HDV positive individuals in rural Sindh** SS. Hamid

Virology: the latest insights

81 **Paired liver and serum deep sequencing reveals differences between circulating HDV and intrahepatic viral populations** J. Ringlander

Immunology update and spatial transcriptomics

37 **Identification of GBP3 as a Novel Host Factor Required for Hepatitis Delta Virus Recognition by Hepatocytes** R. Fouillé

DIAGNOSIS AND NATURAL HISTORY

Diagnostics update

83 **Quantitative anti-HDV measurement as a diagnostic surrogate of HDV replication** E. Dileo

Natural history

69 **Predictors of advanced chronic liver disease (ACLD) in patients with hepatitis delta virus (HDV) infection: does the genotype matter?** M. Cardoso

CURRENT AND NEW ANTIVIRAL TREATMENTS

Long-term outcomes in BLV-treated patients

56 **Clinical and economic value of early treatment with bulevirtide in chronic hepatitis delta virus** R. Dominguez

3 **Hepatic recompensation according to Baveno VII in decompensated chronic hepatitis Delta treated with bulevirtide: a multicenter experience** M. Meszaros

Other therapeutic approaches for HDV

95 **Predicting time to cure in HDV patients treated with bulevirtide and pegylated interferon-alpha in the SEE-D trial** H. Dahari

104 **Histologic improvement and reduction in necroinflammation with lonafarnib-based therapy in chronic hepatitis delta: phase 3 D-LIVR trial** N. Reau

118 **The efficacy and safety of siRNA ozisiran in patients with chronic hepatitis D: Interim results through treatment Week 36 from the phase 2a RC04T001 trial** K. Lindahl

EPIDEMIOLOGY, VIROLOGY AND IMMUNOLOGY

Global and Local Epidemiology

2 **Hepatitis D remains overrepresented and undertreated in prison populations: data from Catalonia, Spain**
A. Marco, A. Palom, I. Abdo, A. Rando-Segura, L. Calatayud, G. Fernández-Rivas, A. Sellés, S. Mormeneo , D. Pérez del Campo, E. del Corral, ED. Gil-Tubella, M. Buti

13 **Integration of reflex hepatitis D virus screening into the national viral hepatitis elimination programme in Uzbekistan**
M. Khodjaeva, E. Musabaev, I. Egamova, V. Rakhimova, E. Joldasova

14 **Single-Center Experience on Rates of Hepatitis D Testing and Electronic Medical Record Coding in Patients with Known Hepatitis B Infection**
E. Hall, D. Rosario, N. Reau

17 **High prevalence of HDV and HBV detected amongst household contacts of HDV positive individuals in rural Sindh**
A. Ali, H. Ahmed, SM. Channa, C. Strobel, M. Rodgers, S. Gawel, F. Averhoff, G. Cloherty, E. Khan, N. Ghanchi, SS. Hamid

31 **Real-world adherence to HDV reflex testing among HBsAg-positive patients in Pakistan: Are we missing HDV?**
F. Nadeem, S. Memon, U. Ghani, A M . Burney, H. Soomro, S. Ali

35 **Global burden and geographic concentration of hepatitis delta virus infection across 195 countries in 2020: A modeling study**
M. Papatheodorid, J. Paik, K. AlNaamani, G. Papatheodoridis, M. Buti, A. Paik, T. Kushner, C. Villela-Nogueira, S. Gidaagaya, B. Munkhbat, M. Yu, J. Ong, Y. Eguchi, M. El-Kassas, P. Lampertico, Y. Yilmaz, C. Spearman, Z. Younossi

36 **Clinical phenotype of hepatitis D according to HIV serostatus: results from the nationwide DDR Spain cohort**
A. Alberola, A. de Salazar, A. Fuentes, R. Carracedo, M. Illescas-López, L. Pérez-Rodríguez, A. Vázquez-Blanquiño, M. Cabezas Fernández, C. Freyre, B. Becerril, I. Viciana, I. López-Rodríguez, N. Montiel Quezel-Guerraz, S. Bernal, J. Borrego, E. Ramírez Arellano, C. Liébana-Martos, F. Franco Álvarez de Luna, M. Lozano, I. de Toro, A. Sampedro, A. Pérez, S. Algarate, P. Fraile, D. Ocete, I. Corrales, O. Martínez, V. Domínguez, N. Orta, S. Sabater Vidal, L. Navarro, E. Aguirre, J. Magraner Egea, A. Vallejo, M. Aroca, T. Tosco Núñez, M. Lara, M. Pena, A. Rodríguez-Fernández, A. González Praetorius, E. Simarro Córdoba, A. Beteta, C. Gómez, M. Rodríguez Escudero, J. García Díez, M. Sandoval Torrientes, R. Sáez, P. Tajada Alegre, B. Lorenzo, M. García Valero, S. García-de Cruz, S. Garcinuño, S. Muñoz, H. Lorenzo Juanes, M. Vidal-Acuña, L. Moldes, N. Calvo, M. Gude, P. Ordóñez, S. Cortizo, M. Blasco, I. Falces, J. Galán, A. Arribi, R. Alonso, A. Iborra, M. del Amor Espín, E. Cascales, M. Nuñez, J. Galán Ros, A. Miqueleiz, L. Elorduy, M. Macho, C. Gómez, P. Liendo, M. Montes Ros, A. Aguilera, F. García

39 **Where should we look for hepatitis D? Community versus hospital-based screening in Romanian migrants in Catalonia, Spain.**
A. Palom, J. Gómez i Prat, T. Rafi, S. Malik, L. Buldum, I. Abdó, A. Marco, P. Huelin, C. Aracil Blanch, C. Lopez, T. Balari, J. Castellote, R. Maria Morillas, M. Buti

65 **National registry of patients with hepatitis D: real-world clinical practice data in Spain**
A. Pocurull, A. Palom, Á. Giráldez, JC Ruiz Cobo, M. Casado, S. Lorente, J. García-Samaniego, M. Molina, R. González Monasterio, I. Fernández, C. Delgado, J. Cabezas, MJ. Devesa, JM. Rosales, N. García Gimeno, M. García-Retortillo, MD. Antón Conejero, R. Ríos, V. Escrich Iturbe, M. Rodríguez, M. Fernández Bermejo, M. Hernández-Conde, P. Rendón Unceta, M. Riveiro Barciela, X. Forn, M. Buti, S. Lens

74 **Epidemiology and clinical characteristics of hepatitis delta virus infection in Belgium: Final results of a nationwide double HDV reflex testing study**
M. Coessens, F. Lemaitre, I. Roukaerts, J. Wawrzyniak, M. Steverlynck, M. Van Esbroeck, BJ. Visser, M. Reda, M. De Vos, M. Reynders, H. Orlent, H. Vanpoucke, C. De Vloo, M. De Spiegeleer, J. Van Acker, L. Coremans, T. Banica, E. Padalko, X. Verhelst, H. Besse-Hammer, L. Lasser, A. Scohy, G. Zorzi, Y. Horsmans, N. Yin, C. Moreno, S. Goes, A. Van Dalem, S. François, P. Beckers, MP. Hayette, J. Delwaide, S. Vandamme, H. Dahma, S. Van den Wijngaert, T. Sersté, K. Hoet, M. Van Herck, P. Bruynseels, N. Van Gasse, S. Bourgeois, W. Verlinden, M. Mukovnikova, A. Vodolazkaia, S. Van Gucht, T. Vanwolleghem

84 **The Economic Burden of Chronic Hepatitis Delta Treatment in Mongolia**
G. Jargalsaikhan, B. Dashtseren, B. Narantuya, T. Ulziibadrakh, O. Lkhagva-Ochir, N. Dashdorj

85 **Seroprevalence and viral biomarker characterization of hepatitis D infection in treatment naive-infected blood donors with hepatitis B in Cameroon**
R. Kamga Wouambo, N. Ashukem Taku, N. S. Ateba, M. Pfefferkorn, S. Nkongolo, GE. Gnouamozi, M. Matz-Soja, S. Urban, T. Berg, F. van Bömmel, F. Ngo Nsack

89 **Reflex testing reveals a significant HDV burden across Europe and increases HDV diagnosis at an early stage**
I. Grossi, R. Salpini, C. Tramontozzi, I. Alexiev, L. Baiocchi, L. Banica, T. Banica, J. Begovac, B. Benkoova, A. Bertoli, S. Bopegamage, C. Caudai, S. D'anna, T. Demir, C. Devaux, A. Di Lorenzo, G. Fernández-Rivas, K. Gazdikova, A. M. Geretti, E. Golkocheva-Markova, S. Grelli, E. Heger, G. Iserentant, L. Jancoriene, L. Svetikas, R. Kaiser, N. Kokkinos, I. Lazarevic, I. Milosevic, V. Lazureanu, K. Leuzinger, M. Lindh, J. Llibre, M. Lunar, U. Mickute, J. Mihale, I. Milosevic, O. Mor, D. Nierhoff, D. Otelea, P. Paba, E. Padalko, L. Piermatteo, M. Poljak, A. Riccio, M. Ruzic, L. Sarmati, G. Torre, A. M. Tudor, A. Vata, K. Tulay Yalçinkaya, D. Yildiran, M. Zazzi, A. Wensing, V. Svicher

100 **Searching for HDV to Find HBV infection; Impact of HDV Screening in Detecting New HBV Infections**
I. Zagni, R. Stupia, F. Paolo Bonfante

101 **Hepatitis delta screening and treatment cascade among people with HIV and chronic hepatitis B in Milan**
T. Clemente, A.R. Raccagni, R. Lolatto, H. Hasson, E. Messina, M. Ripa, V. Spagnuolo, A. Danise, M. Guffanti, P. Cinque, D. Canetti, S. Nozza, A. Castagna

52 **Opportunistic hepatitis screening reveals a hidden burden of hepatitis d and advanced liver fibrosis among hbsag-positive patients presenting with gastrointestinal symptoms in Pakistan**
F. Nadeem, U. Ghani, S. Memon, B. Kadir, R. Bhatti, AH. Soomro

Virology: the latest insights

10 **Precision-cut liver slices as a model for evaluating therapeutic agents against HBV and HDV**
M. Michelet, A. Roca Suarez, M. Plissonnier, A. Dubois, A. Diederichs, S. Heintz, M. Saez-Palma, M. Ben Abu, X. Grand, A. Favre, A. Chédotal, N. Van Renne, S. Fletcher, F. Mithieux, P. Bonnot, A. Dupré, N. Mouton, M. Rivoire, S. Phillips, E. Palma, S. Chokshi, F. Zoulim, B. Testoni

11 **Interferon Response and Cell Division–Mediated Spread of Patient-Derived Hepatitis D Virus Strains**
GE. Gnouamozi, J. Ringlander JB. Stenbäck, L. Mellert, F. Donati, S. Nkongolo, S. Urban

12 **A novel in vitro hepatocyte model of chronic propagative Hepatitis Delta Virus infection for long-term antiviral evaluation and host factor discovery**
F. Bernardin, F. Pastor, C. Pons, R. Fouillé, O. Diaz, F. Habersetzer, TF. Baumert, ER. Verrier, D. Durantel1 and J. Lucifora

15 **What is the relationship between HBV DNA, HDV RNA and liver fibrosis among persons with HBV/HDV co-infection in Ethiopia?**
T. Simbo, W. Abegaz, F.Schlund, F. Le Gal, A. Gerber, S. Zheng, A. Negash, F. Gudisa, D. Birhanu, A. Hussen, W. Cheneke, E. Gudina, S. Nkongolo, F. Lempp, N. Berhe, H. Mekonnen, L. Rossvoll, S. Urban, A. Johannessen

18 **A new humanized mouse model demonstrates HBV DNA integration-driven HDV spread mimicking chronic hepatitis D**
C. Hingst, M. Schäfer, T. Volz, A. Volmari, K. Riecken, L. Bitar, M. Lütgehetmann, M. Zimmermann, B. Fehse, M. Dandri, L. Allweiss

21 **Kinetics of HBcrAg during Bulevirtide monotherapy in patients with HDV-related cirrhosis: a single-center real-world study**
E. Degasperi, F. Facchetti, D. Sambarino, C. Scholtes, B. Testoni, S. Uceda Renteria, MP. Anolli, C. Charre, ML. Plissonnier, R. Perbellini, A. Callegaro, M. Levrero, F. Zoulim, P. Lampertico

29 **Host immunogenetics and first sequencing-based characterization of HDV in Uzbekistan**
E. Kazakova, E. Musabaev, Z. Ismailova, M. Khodjaeva

30 **Association of IL28B gene polymorphisms rs8099917 and rs12979860 with progression of chronic hepatitis D**
D. Abdurakhimova, N. Ibadullaeva, A. Khikmatullaeva, N. Kan

45 **One protein, many roles: Large HDAg controls viral assembly, replication and cytopathic effects to sustain viral persistence**
B. Zehnder, J. Bauer, Y. Ni, Z. Zhang, A. Beer, A. Prawira, S. Urban

61 **Treatment of hbv-hdv hepatitis in a solid organ transplant recipient patient: a case report**
E. Gabrielli, C. Valeriani

51 **Cell proliferation reduces innate antiviral defenses and promotes HDV spread in primary human hepatocytes in vivo**
A. Volmari, T. Volz, J. Chen, L. Allweiss, M. Lütgehetmann, S. Fletcher, M. Holdorf, M. Dandri

57 **Pre-treatment and on-treatment markers of HBV cccDNA transcription predict virological response in chronic hepatitis D treated patients with pegylated-interferon or Bulevirtide**
I. Carey, Z. Cargill, M. Anderson, J. Lok, T. Fortney, G. Cloherty, G. Dusheiko, K. Agarwal

59 **Comparative Laboratory Evaluation of the RoboGene HDV RNA Quantification Kit 2.0 for Quantitative Detection of Hepatitis D Virus RNA**
LZ. Alieva, EA. Joldasova, NG. Kan, DT. Suyarkulova, RH. Juraev, EI. Musabaev

71 **Hepatitis-B core-related antigen (HBcrAg), phosphorylated HBcAg , and HBsAg isoforms as biomarkers of viral activity in chronic HDV infection: Do they mirror HDV RNA status?**
I. Carey, Z. Cargill, M. Anderson, R. Geissler, T. Fortney, J. Lok, G. Cloherty, G. Dusheiko, K, Agarwal

76 **Clinical and virological characteristics of patients with low HDV RNA: HBV transcriptional activity persists despite minimal replication**
I. Carey, Z. Cargill, M. Anderson, J. Lok, T. Fortney, R. Geissler, G. Cloherty, G. Dusheiko, K. Agarwal

81 **Paired liver and serum deep sequencing reveals differences between circulating HDV and intrahepatic viral populations**
J. Ringlander, JB. Stenbäck, M. Andersson, G. Rydell, M. Lindh, M. Kann

91 **Discordance between two peripheral biomarkers of cccDNA transcriptional activity, namely HBV core related antigen and HBV RNA, in HBV-HDV co-infection.**
J. Lok, M. Anderson, T. Fortney, Z. Cargill, G. Cloherty, J. McKeating, G. Dusheiko, K. Agarwal, I. Carey

99 **Health care resource utilisation and costs by disease state in adults with hepatitis delta virus in the United States**
R. Wong, R. Gish, S. Dhuliawala, G. Leung, J. Lim, M. Rock, C. Kim

77 **Phylogeography and epidemiological history of hepatitis delta virus genotype 3 in South America**
L. Honorato, M. Gouvea, W. Braga, A. da Costa, M. Rodgers, M. Berg, C. Silveira, E. Kallas, M. Thomazella, A. de Paula, M. Castilho, Y. Rodrigues, H. Paião, M. de Freitas, L. Ribeiro, D. Dall'Acqua, J. Queiroz, J. Salcedo, T. Dantas, R. Barboza, T. Tozetto-Mendoza, F. Averhoff, S. Witkin, G. Cloherty, C. Mendes-Correa

78 **Phylogeographic reconstruction reveals recent African–Atlantic dispersal of hepatitis delta virus genotype 8**
L. Honorato, K. Fassihi, S. Witkin, C. Mendes-Correa

Immunology update and spatial transcriptomics

37 **Identification of GBP3 as a Novel Host Factor Required for Hepatitis Delta Virus Recognition by Hepatocytes**
R. Fouillé, C. Pons, R. Barnault, E. Verrier, D. Durantel and J. Lucifora

38 **Bulevirtide treatment reduces activation of T cells in chronic HDV infection**
S. Chowdhury, R. Hoblos, H. Begali, M. Anim, C. Jacobsen, M. Lissek, E.A. Oyinloye, A. Carpentier, CS. Falk, ARM. Kraft, M. Cornberg, H. Wedemeyer, L. Sandmann, H. Kefalakes

66 **Identification of peripheral immune cell populations in HDV untreated and Bulevirtide-treated patients**
J. Pérez-Garreta, A. Palom, A. Carvalho-Gomes, I. Llaosa Ferrera, D Tabernero, A. Rando Segura, J. Romero, M. Berenguer, J.C. Ruiz Cobo, M. Riveiro-Barciela, M. Buti, M.F. Cortese

117 **Bulevirtide increases taurocholic acid in hepatitis D patients leading to reduced NK cell proliferation capacity**
P. Chen, C. Dietz-Fricke, T. More, K. Hiller, K. Deterding, N. Woller, H. Wedemeyer

62 **An immunocompetent Syrian hamster model of persistent HDV mono-infection validated for antiviral testing**
E. Broeckhoven, Y. Vanhees, F. Van Bavel, R. Gijsbers, C. Van den Haute, Y.A. Alpizar, K. Dallmeier

63 **A high-content imaging-compatible innate immune response-based reporter system for HDV antiviral screening**
Y. Vanhees, E. Broeckhoven, V. Neven, Y.A. Alpizar, K. Dallmeier

DIAGNOSIS AND NATURAL HISTORY

Diagnostics update

7 **Pan-genotypic detection and whole-genome sequencing of hepatitis D virus using the Illumina Viral Surveillance Panel v2**
F. Le Gal, S. Dziri, V. Delagarde, A. Gerber, D. Roulot, S. Brichler

32 **Global practice patterns in hepatitis D virus screening and management: Results from an international survey of healthcare providers**
M. Papatheodoridi, M. Buti, G. Papatheodoridis, P. Charatcharoenwitthaya, A. Bhadoria, J. Fan, B. Pearlman, C. Villela-Nogueira, S. Singh, S. Kakizaki, W. Chan, A. Kulkarni, A. Singal, A. Ostojić, J. Crespo, C. Tzeuton, J. Lai, L. Kondili, M. Batmunkh, M. Ayurzana, M. Yu, G. Goh, D. Karagiannakis, E. Lytvyak, A. Goel, K. AlNaamani, C. Spearman, I. Jacobson, T. Kushner, D. Duger, Y. Eguchi, M. El-Kassas, S. Gidaagaya, S. Gordon, S. Khaderi, P. Lampertico, M. Lee, B. Namdag, P. Ocama, M. Pessoa, N. Pyrsopoulos, F. Russo, Y. Yilmaz, L. Henry, F. Nader, A. Racila, M. Stepanova, J. Ong, Z. Younossi

40 **Evaluation of dried blood spots for automated hepatitis D nucleic acid testing**
S. Retzlaff, P. Rosenstock, AJ. Castillo, K. Rottengatter

47 **Longitudinal HDV RNA monitoring reveals virological rebound despite sustained HIV and HBV suppression in a cirrhotic patient**
E. Altavilla, L. Bortolani, C. Carafa, S. Figliomeni, A. Mauro, F. Alessi, G. d'Ettorre

54 **Development of a local panel for quality control of hepatitis delta virus PCR diagnostic kits**
SA. Tursunova, RK. Jurayev, NG. Kan, DT. Suyarkulova

55 **Vibration-controlled transient elastography shows a high diagnostic value in the exclusion of cirrhosis and the detection of significant fibrosis in patients with chronic hepatitis D virus infection**
A. Hahn, D. Roulot, E. Degasperi, R. Layese, H. Wedemeyer, S. Aleman, P. Lampertico, K. Deterding, H. Kefalakes, L. Sandmann

60 **Implementation of reflex testing for hepatitis Delta into Uzbekistan's National Strategy and Action Plan for the Elimination of Parenteral Viral Hepatitis (2026–2030): validation of diagnostic screening tools**
L. Alieva, E. Joldasova, N. Kan, R. Juraev, E. Musabaev

64 **Performance evaluation of the Cobas HDV assay for automated HDV RNA detection and quantification: implications for clinical diagnostics and treatment monitoring in patients with HDV infection**
A. Kessler, S. Suresh Kumar, S. Giraldez Martinez, S. Zenebe Gebreab, M. Lin, J. Young, A. Hiergeist, B. Seiverth, C. Voitenleitner, P. Lampertico, M. Luetgehetmann

68 **Positive impact of anti-HDV reflex testing in all HBsAg+ patients**
C. Valente, A. Carmo, R. Carvalho, J. Vaz, C. Lopes, T. Reis, P. Silva, G. Marques, L. Araújo

70 **Inadequate HDV screening among patients with HBV in pregnancy and association of HDV with adverse pregnancy outcomes: results from a multicenter retrospective study**
C. McNatt, H. Mallick, T. Kushner

83 **Quantitative anti-HDV measurement as a diagnostic surrogate of HDV replication**
GP. Caviglia, E. Dileo, G. Gioiello, A. Olivero, G. Mengozzi, A. Ciancio, G. Ricco, B. Coco, L. Marinaro, G. Cariti, C. Taibi, G. D'Offizi, R. Cotugno, GA. Niro, A. Loglio, M. Viganò, C. Magni, D. Angrisani, V. Messina, V. Cossiga, M. Milella, G. Verucchi, E. Pontali, M. Pirisi, C. Coppola, A. Izzi, V. Di Marco, T. Santantonio, A. Marrone, N. Coppola, M. Rizzi, A.M. Cattelan, P. Toniutto, FR. Ponziani, R. Viganò, A. Federico, G. Bertino, M. Puoti, A. Civolani, M. Distefano, MR. Brunetto, M. Rizzetto, on behalf of the HDV DESCRIBE Study Group.

87 **Longitudinal comparison of RoboGene HDV RNA Quantification Kit 2.0 and 3.0 and an in-house HDV RNA assay during BLV and PEG-INF treatment**
M. Pfefferkorn, J. Seltmann, M. Matz-Soja, Beatrix Gey, C. Früchtel, A. Reinhardt, F. van Bömmel

92 **Diagnostic and care pathway delays among chronic hepatitis D patients in Pakistan: a mixed-methods study**
U. Arzoo, Z. Abbas

115 **Clinical performances of the Roche Cobas HDV RNA quantification assay in untreated and Bulevirtide-treated CHD patients: a 4-assay comparative study**
MP. Anolli, S. Uceda Renteria, E. Degasperi, F. Facchetti, D. Sambarino, M. Borghi, R. Perbellini, R. Soffredini, S. Monico, A. Callegaro, P. Lampertico

Natural history

48 **Landmark Machine Learning Analysis to Identify One-Year Risk of Advanced Liver Disease in Individuals with Hepatitis Delta Virus Infection**
L. Telep, L. Hong, B. Zhao, A. Singer, R. Wong

67 **Long-term natural history and prognostic factors in patients with chronic hepatitis delta: a single-center retrospective longitudinal study**
S. Laviola, I. La Scuola, P. Ferrari, F. Federici, S. Parisse, A. De Santis, F. Ferri

88 **A pediatric case of chronic hepatitis B/D receiving multiple courses of antiviral therapy**
F. Donati, N. Dashdor, G. Jargalsaikhan, Z. Doljoo, P. Michl, S. Urban, S. Nkongolo

69 **Predictors of advanced chronic liver disease (ACLD) in patients with hepatitis delta virus (HDV) infection: does the genotype matter?**
M. Ferreira Cardoso*, E. Pádua*, H. Coelho, D. Toscano, J. Branco, F. Peruzzu, G. Cristóvão, D. Abrantes, F. Pinto Ferreira, N. Faria, P. Pacheco, M. Manata, M. Canhoto, C. Silva, A. Reis, A. Vieira, A. Vaz, H. Cardoso, R. Pinho, L. Santos, R. Carvalho, I. Costa Santos, F. Capinha, I. Medeiros, C. Batouxas, P. Mesquita, F. Borges Santos, R. Bragança, C. Valente, A. Martins, F. Calinas, H. Cortes Martins, P. Nogueira, M. Verdelho Machado
**Both authors contributed equally to this work.*

103 **Discordance between liver stiffness measurement and FIB-4 and its impact on the long-term risk of liver-related events in chronic hepatitis D**
H. Kamal, G. Jargalsaikhan, S. Enkhtaivan, K. Lindahl, B. Dashtseren, O. Lkhagva-Ochir, T. Ulziibadrakh, A. Bungert, N.B Dashdorj and S. Aleman

HCC in HDV: pathogenesis, incidence and predictors

8 **Hepatocellular Carcinoma in Chronic Hepatitis D: A Nationwide Benchmark Pre-Bulevirtide era from the Italian PITER Cohort**
G. Brancaccio, MG. Quaranta, ME. Tosti, B. Coco, MR. Brunetto, GB. Gaeta, LA. Kondili on behalf of PITER Collaborating Investigators

42 **HCC risk stratification during long-term Bulevirtide therapy: performance of PAGE-B and AMAP in compensated HDV cirrhosis**
MP. Anolli, E. Degasperi, D. Sambarino, M. Borghi, R. Perbellini, L. Gheorghe, M. Chitul, C. Schramm, H. Schmidt, M. Jachs, T. Reiberger, I. Carey, K. Agarwal, M. Buti, A. Palom, G. D'Offizi, F. di Maria, C. Zöllner, F. Tacke, C. Dietz-Fricke, H. Wedemeyer, M. Papatheodoridi, G. Papatheodoridis, F. van Bömmell1, S. Lens, MR. Brunetto, A. Federico, E. Rosselli Del Turco, M. Meszaros, A. Ciancio, A. Giráldez-Gallego, F. Calinas, F. Zoulim, S. Aleman, N. Semmo, S. Metivier, C. Coffin, S. Poulin, A. Mangia, MN. Hilleret, U. Merle, M. Cardoso, A. Martins, C. Gouveia, K. Doucette, S. Borgia, M. Viganò, TA. Santantonio, N. Coppola, A. Pellicelli, J. Foucher, B. Roche, X. Causse, L. D'Alteroche, J. Dumortier, N. Ganne, F. Heluwaert, I. Ollivier, D. Roulot, I. Rosa, I. Costa Santos, AM. Vieira, F. Pileri50, M Maracci51, M Tonnini52, JP Arpurt53, K Barange54, E Billaud55, S Pol56, A Gervais57, A Minello58, M Puoti59, A Horta60, M Machado61, D Fernandes, J. Oliveira, J. Vaz Alves, P. Lampertico

46 **Management of hepatocellular carcinoma in patients with chronic HBV-HDV infection undergoing Bulevirtide therapy**
L. Iliescu

53 **Hepatitis D in Hepatitis B-associated hepatocellular carcinoma: a real-world Pakistani cohort reveals a high burden and advanced presentation**
U. Ghani, F. Nadeem, S. Memon, B. Kadir, R. Bhatti

Baveno VIII update

44 **Baveno criteria in HDV-related cirrhosis: toward a disease-specific model to safely avoid screening endoscopy (Baveno-HDV)**
MP. Anolli, E. Degasperi, G. Tosetti, L. Gheorghe, A. Loglio, A. Ciancio, G. D'Offizi, T. Reiberger, C. Schramm, MR. Brunetto, F. van Bömmel, S. Zaltron, L. Turco, C. Zöllner, TA. Santantonio, I. Carey, A. Federico, L. Sarmati, M. Buti, M. Cardoso, F. Morisco, M. Papatheodoridi, FP. Russo, A. Mangia, P. Toniutto, N. Coppola, Q. Wu, J. Dumortier, EG. Giannini, E. Rosselli Del Turco, S. Aleman, S. De Nicola, M. Maracci, L. Marinaro, M. Milella, A. Pellicelli, B. Pinchera, M. Puoti, D. Roulot, LS. Crocè, I. Maida, U. Merle, A. Pan, O. Torre, F. Pileri, A. Romano, M. Tonnini, P. Vitiello, R. Zampino, F. Cerini, P Lampertico on behalf of the SAVE-D and D-SHIELD investigators

CURRENT AND NEW ANTIVIRAL TREATMENTS

BLV in clinical trials

90 **Immunological predictive factors for treatment response during bulevirtide therapy in HBV-HDV coinfected patients.**
C. Taibi, E. Cimini, G. Grassi, A. Caioli, A. Rianda, F. Cristofanelli, S. Pauciullo, V. Zulian, A.R. Garbuglia, A.M. Geretti, E. Biliotti, G. D'Offizi

112 **Discontinuation of bulevirtide monotherapy in patients with chronic hepatitis D: A prospective multicenter study (D-SOLVE BUL-STOP)**
H. Wedemeyer, J. Kahlhöfer, E. Degasperi, K. Sprinzl, C. Zöllner, S. Nkongolo, D. Sambarino, K. Port, J. Schulze zur Wiesch, B. Bremer, K. Steppich, A. Kraft, H. Kefalakes, A. Großhennig, R. Ringlstetter, L. Sandmann, P Lampertico, K. Deterding, for the D-SOLVE Consortium

109 **Integrated efficacy analysis by HDV and HBV genotypes in patients with chronic hepatitis delta receiving bulevirtide**
T. Stepanova, S. Aleman, T. Asselah, P. Bogomolov, M. Brunetto, V. Chulanov, G.S. Gherlan, P. Lampertico, V. Morozov, O. Sagalova, A. Streinu-Cercel9,14, F. Zoulim, A. Lichtman, M. Li, H. Mo, D. Manuilov, H. Wedemeyer

114 **Long-term treatment with bulevirtide 2 mg improves Fatigue Severity Scale scores in patients with chronic hepatitis delta virus: Results from an exploratory analysis of the Phase 3 MYR301 trial**
M. Buti, H. Wedemeyer, S. Aleman, V. Chulanov, V. Morozov, O. Sagalova, T. Stepanova, R.G. Gish, S. Zeuzem, J. Schulze zur Wiesch, M. Cornberg, M.R. Brunetto, D. Manuilov, A. Lichtman, M. Rock, C. Kim, S. Pandey, B. Singh, P. Lampertico

116 **No impact of antidrug antibodies on the efficacy of bulevirtide in chronic hepatitis delta: Insights from a 96-week integrated analysis**
P. Lampertico, S. Aleman, H. Wedemeyer, A. Streinu-Cercel, P. Bogomolov, V. Morozov, T. Stepanova, S. Lazar, M. Brunetto, V. Chulanov, G.S. Gherlan, O. Sagalova, R-C. Mercier, L. Caro, M. Li, A. Lichtman, D. Manuilov, T. Asselah, A. Blank, F. Zoulim, M. Cornberg, S. Zeuzem

Long-term outcomes in BLV-treated patients

16 **Pregnancy outcomes following bulevirtide exposure during pregnancy: An analysis of clinical trial and postmarketing data**
P. Jhand, A. Rodriguez Dominguez, D. Shing, F. Christian-Cox, S. Tseng, D. Manuilov, A. Lichtman

20 **Bulevirtide monotherapy prevents liver decompensation but not HCC in patients with HDV-related cirrhosis: 3-year results from an inverse probability-weighted European case-controlled study**
E. Degasperi, A. De Silvestri, D. Roulot, MP. Anolli, L. Gheorghe, M. Chitul, C. Schramm, H. Schmidt, M. Jachs, T. Reiberger, J. Foucher, S. Metivier, M. Buti, A. Palom, G. D'Offizi, F. De Maria, C. Zöllner, F. Tacke, C. Dietz-Fricke, H. Wedemeyer, M. Papatheodoridi, G. Papatheodoridis, I. Carey, K. Agarwal, F. Van Bömmell, MR. Brunetto, E. Rosselli del Turco, A. Ciancio, S. Lens, Á. Giráldez-Gallego, F. Calinas, F. Zoulim, S. Aleman, N. Semmo, A. Mangia, MN. Hilleret, U. Merle, M. Cardoso, J. Branco, C. Gouveia, TA. Santantonio, N. Coppola, A. Pellicelli, B. Roche, X. Causse, L. D'Alteroche, J. Dumortier, N. Ganne, F. Heluwaert, I. Ollivier, A. Loglio, A. Federico, F. Pileri, M. Maracci, M. Tonnini, JP. Arpurt, K. Barange, E. Billaud, L. Parlati, A. Gervais, A. Minello, I. Rosa, I. Costa Santos, F. Velasco, M. Puot A. Horta, M. Machado, D. Fernandes, J. Oliveira, J. Vaz Alves, J. Flaherty, P. Lampertico

22 **Long-term clinical and virological outcomes of Bulevirtide monotherapy up to 4 years in CHD patients with cirrhosis: the SAVE-D study**
E. Degasperi, MP. Anolli, D. Sambarino, M. Borghi, R. Perbellini, L. Gheorghe, M. Chitul, C. Schramm, H. Schmidt, M. Jachs, T. Reiberger, I. Carey, K. Agarwal, M. Buti, A. Palom, G. D'Offizi, F. De Maria, C. Zöllner, F. Tacke, C. Dietz-Fricke, H. Wedemeyer, M. Papatheodoridi, G. Papatheodoridis, F. Van Bömmell, S. Lens, MR. Brunetto, A. Federico, E. Rosselli Del Turco, M. Meszaros, A. Ciancio, Á. Giráldez-Gallego, F. Calinas, F. Zoulim, S. Aleman, N. Semmo, S. Metivier, C. Coffin, S. Poulin, A. Mangia, MN. Hilleret, U. Merle, M. Cardoso, A. Martins, C. Gouveia, K. Doucette, S. Borgia, A. Loglio, TA. Santantonio, N. Coppola, A. Pellicelli, J. Foucher, B. Roche X. Causse, L. D'Alteroche J. Dumortier, N. Ganne, F. Heluwaert, I. Ollivier, D. Roulot, I. Rosa, C. Fonseca, AM. Vieira, F. Pileri, M. Maracci M. Tonnini, JP. Arpurt, K. Barange, E. Billaud, L. Parlati, A. Gervais, A. Minello, M. Puoti, A. Horta, M. Machado, D. Fernandes, J. Oliveira, J. Vaz Alves, P. Lampertico

23 **Characterization of virological breakthroughs under Bulevirtide monotherapy: combined data from the SAVE-D and D-SHIELD cohorts**
E. Degasperi, MP. Anolli, D. Sambarino, M. Borghi, R. Perbellini, L. Gheorghe, A. Loglio, A. Ciancio, G. D'Offizi, C. Schramm, T. Reiberge, MR. Brunetto, K. Agarwal, M. Buti, S. Zaltron, F. Tacke, H. Wedemeyer, M. Papatheodoridi, F. Van Bömmell, S. Lens, A. Federico, E. Rosselli Del Turco, M. Meszaros, Á. Giráldez-Gallego, F. Calinas, M. Milella, L. Turco, A. Di Lorenzo, M. Tamé, P. Toniutto, A. Gasbarrini, L. Marinaro, FP. Russo, A. Gori, I. Maida, TA. Santantonio, R. Bruno, EG. Giannini, I. Cacciola, F. Morisco, A. Mangia, S. De Nicola, A. Romano, M. Maracci, B. Pinchera, SL. Crocè, P. Lampertico on behalf of the SAVE-D and D-SHIELD investigators

28 **Mathematical modeling of 144-week bulevirtide monotherapy in HDV-infected patients with compensated cirrhosis and CSPH**
A. Mhlanga, L. Shekhtman, E. Degasperi, M.P. Anolli, S.C. Uceda Renteria, D. Sambarino, M. Borghi, R. Perbellini, F. Facchetti, A. Callegaro, S.J. Cotler, H. Dahari, P. Lampertico

43 **Bulevirtide provides comparable virological control regardless of cirrhosis status: analysis of treatment response and breakthroughs from the D-Shield multicenter prospective study**
MP. Anolli, E. Degasperi, G. D'Offizi, A. Rianda, A. Loglio, M. Viganò, A. Ciancio, Y. Troshina, MR. Brunetto, B. Coco, A. Zaltron, O. Nozza, M. Milella, E. Rosselli Del Turco, L. Turco, A. Di Lorenzo, M. Tamé, P. Toniutto, A. Gasbarrini, L. Marinaro, FP. Russo, C. Magni, I. Maida, A. Federico, TA. Santantonio, R. Bruno, EG. Giannini, I. Cacciola, G. Svegliati Baroni, F. Morisco, A. Mangia, S. De Nicola, A. Romano, M. Maracci, B. Pinchera, SL. Crocè, F. Pileri, R. Zampino, M. Persico, P. Pozzoni, A. Zoncada, A. Pellicelli, N. Coppola, M. Tonnini, E. Grassi, A. Soria, P. Caraceni, M. Dalla Bella, I. Arena, V. Esposito, P. Vitiello, M. Puoti, P. Lampertico

50 **Early gamma-glutamyl transferase decline mirrors virological response during bulevirtide therapy in chronic hepatitis D: a real-world longitudinal study**
EA. Gabor, L. Foroghi Biland, A. Alfieri, S. Ampollini, C. Boni, G. Missale

POSTER EXHIBITION

56 **Clinical and economic value of early treatment with bulevirtide in chronic hepatitis delta virus**
M. Buti, JL. Calleja, MA. Rodríguez, R. Domínguez-Hernández, N. Espinoza-Cámac, V. Martín-Escudero, H. Cantero

58 **Improvement of non-invasive fibrosis tests and clinically significant portal hypertension according to Baveno VII criteria during Bulevirtide monotherapy in patients with HDV-related cirrhosis: a longitudinal analysis of the SAVE-D study**
E. Degasperi, MP. Anolli, D. Sambarino, M. Borghi, R. Perbellini, L. Gheorghe, M. Chitul, C. Schramm, H. Schmidt, M. Jachs, T. Reiberger, I. Carey, K. Agarwal, M. Buti, A. Palom, G. D'Offizi, F. De Maria, C. Zöllner, F. Tacke, Q. Wu, H. Wedemeyer, M. Papatheodoridi, G. Papatheodoridis, F. Van Bömmell, S. Lens, MR. Brunetto, A. Federico, E. Rosselli Del Turco, M. Meszaros, A. Ciancio, Á. Giráldez-Gallego, F. Calinas, F. Zoulim, S. Aleman, N. Semmo, S. Metivier, C. Coffin, S. Poulin, A. Mangia, MN. Hilleret, U. Merle, M. Cardoso, A. Martins, C. Gouveia, K. Doucette, S. Borgia, A. Loglio, TA. Santantonio, N. Coppola, A. Pellicelli, J. Foucher, B. Roche, X. Causse, L. D'Alteroche, J. Dumortier, N. Ganne, F. Heluwaert, I. Ollivier, D. Roulot, I. Rosa, C. Fonseca, AM. Vieira, F. Pileri, M. Maracci, M. Tonnini, JP. Arpurt, K. Barange, E. Billaud, L. Parlati, A. Gervais, A. Minello, M. Puoti, A. Horta, M. Machado, D. Fernandes, J. Oliveira, J. Vaz Alves, P. Lampertico

79 **Bulevirtide discontinuation after long-term HDV RNA suppression in patients with CHD: impact of different HDV RNA assays on patient selection and virological outcomes (Robogene 2.0 vs. AltoStar 1.5)**
MP. Anolli, S. Uceda Renteria, E. Degasperi, F. Facchetti, D. Sambarino, M. Borghi, R. Perbellini, R. Soffredini, S. Monico, A. Callegaro, P. Lampertico

82 **Integrated Pharmacogenetic, Pharmacokinetic, and Clinical Evaluation of Bulevirtide in Patients with Chronic Hepatitis D**
J. Cusato, M. Antonucci, A. Palermiti, A. Manca, A. De Nicolò, C. Quarta, A. D'Avolio, G. Di Perri, S. Bonora and L. Marinaro

94 **Viral kinetics modelling of initial and retreatment in HDV patients under bulevirtide monotherapy**
D. Shemla, K. Deterding, L. Shekhtman, S.J. Cotler, A. Mhlanga, E. Degasperi, P. Lampertico, D. Sambarino, L. Sandmann, K. Port, S. Aleman, A. Olsen, M. Jachs, T. Reiberger, M. Brunetto, G. Ricco, H. Dahari, H. Wedemeyer

97 **Real-world effectiveness and safety of Bulevirtide in patients with chronic hepatitis D: a single-center cohort from Romania**
V. Molagic, I. Staicu, A. Mihalache, A. Saran, A. Cozma, D. Neagu, A. Marinescu, C. Gheorghe, C. Tiliscan, R. Nastase, D. Toma, A. Negru, A. Orfanu, S. Arama, V. Arama

102 **Correlation between HDV RNA and anti-HDV dynamics in chronic hepatitis D patients treated with Bulevirtide**
G. Ricco, D. Cavallone, P. Colombatto, B. Coco, F. Oliveri, F. Damone, G. Petralli, V. Romagnoli, A. Salvati, L. Surace, A. Calì, B. Vianello, F. Bonino, M. R. Brunetto

110 **Bulevirtide treatment is associated with improvements in disease severity in patients with detectable hepatitis delta virus RNA: Results from a real-world study in Europe**
P. Lampertico, F. Hennessy, T. Pennant, D. Graham, F. Barrable, A. Hinds, C. Burk, C. Kim, M. Rock, M. Buti

111 **Association of bulevirtide use with changes in ALT: Results from a real-world study in Europe**
P. Lampertico, F. Hennessy, T. Pennant, D. Graham, F. Barrable, A. Hinds, C. Burk, C. Kim, M. Rock, M. Buti

73 **Real-world 72-week virological and biochemical responses to bulevirtide in Romanian patients with chronic hepatitis D: data from a multicentre registry**
L. Gheorghe, M. Ghioca, M. Chitul, C. Radu, M. Manuc, C. Gheorghe, M. Diculescu, A. Trifan, L. Huiban, M. Radu, F. Căruntu, L. Sandulescu, D. Gheonea, C. Radu, B. Procopet, C. Pop, N. Tiuca, R. Sirli, S. Iacob

75 **Health-related quality of life during bulevirtide treatment in a Romanian cohort**
L. Gheorghe, M. Ghioca, M. Chitul, C. Radu, M. Manuc, C. Gheorghe, M. Diculescu, A. Trifan, L. Huiban, M. Radu, F. Căruntu, L. Sandulescu, D. Gheonea, C. Radu, B. Procopet, C. Pop, N. Tiuca, R. Sirli, S. Iacob

3 **Hepatic recompensation according to Baveno VII in decompensated chronic hepatitis Delta treated with bulevirtide: a multicenter experience**
M. Meszaros, GP. Pageaux, M. Viganò, E. Farina, C Bouzbib, S. Dharancy, T. Antonini, S. Fagiuoli, A. Loglio

Anti-HBs and siRNA combination

9 **SOLSTICE Week 48 subgroup analysis: Impact of BMI on ALT normalization after successful viral control in participants with chronic hepatitis delta virus infection treated with elebsiran and tobevibart**
A. Jucov, T. Asselah, A. Streinu-Cercel, E. Gane, H. Wedemeyer, P. Lampertico, P. Kennedy, M.A. Chattergoon, B.L. Bullard, C. Huang, R. Acosta, S. Chow, C. Hwang, C. Pilowa, T. Correll, K. Agarwal

24 **Efficacy and safety of elebsiran (VIR-2218) in combination with tobevibart (VIR-3434) or tobevibart alone in participants with chronic hepatitis delta virus infection: Week 96 endpoint results from the Phase 2 SOLSTICE trial**
T. Asselah, A. Streinu-Cercel, A. Jucov , E. Gane , H. Wedemeyer, P. Lampertico, P. Kennedy, M.A. Chattergoon, B.L. Bullard, C. Huang, R. Acosta, C. Pilowa9, T. Correll9, K. Agarwal10

Other therapeutic approaches for HDV

4 **Libevitug treatment in chronic hepatitis D: virologic, biochemical, and biomarker improvements through 48 weeks**
S.S. Hamid, Y. Xie, Z. Abbas, C. Wu, X.Z. Wang, A.Majeed, L. Zhang, X.N. Wu, O. Afzal, S.Nazir, H. Zhou, J. Wu, F. Guo, Z.G. Wang, Q. Xu, X. Zhou, L.F. Zou, Y.H. Qi, G.Y. Li, P. Chen, J.Y. Wen, Z.M. Zhou, X.P. Chen, B.Ye, Y. Zhang, B.Chen, J.H. Shui, W.H. Li, J.D. Jia, J.Q.Niu

25 **Brelovitug Monotherapy for the Treatment of Chronic Hepatitis D: Primary 24 Week Efficacy and Safety Results from the AZURE-1 Phase 2b Study**
T. Kushner, D. Yardeni, M. Dobryanska, A. Jucov, D. Dieterich, J. Feld, M. Butsashvili, E. Dolmazashvili, D. Gerov, T. Khuchua, T. Saadi, D. Kaplan, J. Park, D. Pavlov, M. Radicheva, C. Coffin, E. Gane, S. Poulin, I. Jacobson, M. Levy, M. Sulkowski, N. Terrault, K. Doucette, N. Reau, S. Strasser, T. Tanaka, A. Duzik, S. Tan, S. Naim, W. Garner, C. Pace, H. Javanbakht, N. Shulman, S. Hamid, C. Yurdaydin (*P.* D. Weerasinghe)

26 **Brelovitug Monotherapy for the Treatment of Chronic Hepatitis D: Primary 24-Week Efficacy and Safety Results in Patients with Baseline Platelet Counts <100,000/µL from the AZURE-1 Phase 2b Study**
D. Dieterich, D. Yardeni, T. Kushner, M. Dobryanska, A. Jucov, J. Feld, M. Butsashvili, E. Dolmazashvili, D. Gerov, T. Khuchua, T. Saadi, D. Kaplan, J. Park, D. Pavlov, M. Radicheva, C. Coffin, E. Gane, S. Poulin, I. Jacobson, M. Levy, M. Sulkowski, N. Terrault, K. Doucette, N. Reau, S. Strasse, T. Tanaka, A. Duzik, S. Tan, S. Naim, W. Garner, D. Weerasinghe, M. Bosse, N. Shulman, C. Yurdaydin, S. Hamid

86 **Efficacy and Safety of Pegylated Interferon alfa-2a in Patients with Chronic Hepatitis Delta in Mongolia**
G. Jargalsaikhan, B. Narantuya, B. Batkhuu, M. Batkhuu, B. Dashtseren, T. Ulziibadrakh, O. Lkhagva-Ochir, N. Dashdorj

95 **Predicting time to cure in HDV patients treated with bulevirtide and pegylated interferon-alpha in the SEE-D trial**
A. Mhlanga, E. Zavalis, S.J. Cotler, K. Lindahl, L. Shekhtman, S. Cederberg, A. Olsson, N. Björkström, P. Lampertico, H. Wedemeyer, S. Aleman, H. Dahari

96 **Mathematical modeling reveals mechanisms of response to pegylated interferon-alpha in chronic hepatitis D: Insights from the D-LIVR Study**
A. Omesi, L. Shekhtman, A. Mhlanga, T. Heller, C. Koh, J. Glenn, T. Asselah, S. Hamid, D. Yardeni, S.J. Cotler, H. Dahari, O. Etzion

104 **Histologic improvement and reduction in necroinflammation with lonafarnib-based therapy in chronic hepatitis delta: phase 3 D-LIVR trial**
R. Taylor, T. Asselah, O. Etzion, S. Hamid, G. Gherlan, M. Buti Feret, P. Lampertico, A. Turcanu, T. Petrivna, L. Gheorghe, G. Stancu, N. Voronkova, N. Bursukova, S. Aleman, J. Feld, R. Gish, J. Sirois, A. Hirani, H. Agha, L. Kawas, N. Reau, C. Koh, T. Heller, C. Yurdaydin, X. Hua, J. Glenn

105 **Post-treatment response following 48 weeks of lonafarnib therapy: analysis of 24-week follow-up in the phase 3 D-LIVR trial in chronic hepatitis delta**
S. Hamid, O. Etzion, T. Asselah, G. Gherlan, M. Buti Feret, P. Lampertico, A. Turcanu, T. Petrivna, L. Gheorghe, G. Stancu, N. Voronkova, N. Bursukova, S. Aleman, J. Feld, R. Taylor, J. Sirois, A. Hirani, H. Agha, L. Kawas, N. Reau, C. Koh, T. Heller, C. Yurdaydin, X. Hua, J. Glenn.

106 **Clinical significance of ALT dynamics following lonafarnib treatment cessation in the phase 3 D-LIVR trial**
O. Etzion, S. Hamid, T. Asselah, G. Gherlan, M. Buti Feret, P. Lampertico, A. Turcanu, H. Bonkovsky, J. Lewis, J. Ahmad, S. Aleman, J. Feld, R. Taylor, J. Sirois, A. Hirani, H. Agha, L. Kawas, N. Reau, C. Koh, T. Heller, C. Yurdaydin, X. Hua, J. Glenn

107 **A 2log decrease in HDV RNA plus normal ALT 6 months post lonafarnib-based therapy for hepatitis delta virus (HDV) is sufficient for long-term clinical benefit**
C. Yurdaydin, C. Koh, MÖ. Gülnar, O. Metin, E. Yurdcu, S. Özer, O. Keskin, M. Gümüşsoy, E. Bodakçi, X. Deda, ZM. Ellik, S. Aghayeva, G. Gençdal, M. Akyildiz, M. Zeybel, R. Idilman, MA. Bozdayi, I. Choong, N. Dashdorj, N. Dashdorj, E. Mills, O. Harari, T. Heller, JS. Glenn

118 **The efficacy and safety of siRNA ozisiran in patients with chronic hepatitis D: Interim results through treatment Week 36 from the phase 2a RC04T001 trial**
K. Lindahl, M. Hedenstierna, K. Johansson Århem, C. Gahrton, P. Ljungman, C. Millbourn, M. Tremoy, S. Ueckert, S. Svedlund, A. Gabrielsen, P. Lampertico, H. Wedemeyer, S. Aleman

UNMET NEEDS IN HDV

Global modeling of HDV antiviral therapy impact

6 **Clinical Impact of Multidisciplinary Care in an Oncology Patient With HIV and Chronic Viral Hepatitis Receiving Chemotherapy**
AM. Spera, C. D'Amore, V. Conti, A. Filippelli, M. Onofrio, P. Pagliano

34 **Beyond Fibrosis: Chronic Hepatitis D Is Associated with Worse Patient-Reported Outcomes and a Distinct Clinical Burden Compared with Hepatitis B**
M. Buti, G. Papatheodoridis, T. Kushne, M. Papatheodoridi, KM. AlNaamani, C. Villela-Nogueira, B. Munkhbat, S. Gidaagaya, ML. Yu, C. W. Spearman, I. Jacobson, Y. Eguchi, M. El-Kassas, P. Lampertico, Y. Yilmaz, M. Stepanova, J. P. Ong, ZM. Younossi

MASLD/MASH in HBV and HDV

41 **Cardiometabolic profile of european patients with chronic hepatitis delta: insights from the Save-D and D-Shield cohorts**
MP. Anolli, E. Degasperi, L. Gheorghe, A. Loglio, A. Ciancio, G. D'Offizi, M. Jachs, T. Reiberger, C. Schramm, MR. Brunetto, F. Van Bömmel, S. Zaltron, L. Turco, C. Zöllner, TA. Santantonio, I. Carey, A. Federico, M. Tamè, A. Di Lorenzo, M. Buti, F. Calinas, F. Morisco, M. Papatheodoridi, FP. Russo, A. Mangia, P. Toniutto, N. Coppola, Q. Wu, J. Dumortier, EG. Giannini, E. Rosselli Del Turco, S. Aleman, S. De Nicola, M. Maracci, L. Marinaro, M. Milella, A. Pellicelli, B. Pinchera39, M Puoti40, D Roulot41, LS Crocè42, I Maida43, U Merle44, M Cardoso45, A Zoncada46, P Torre47, F Pileri48, A Romano49, M Tonnini50, P Vitiello, R. Zampino, P. Lampertico on behalf of the SAVE-D and D-SHIELD investigators

Liver transplantation for HDV

5 **HDV infection in the liver transplantation setting: less rare than expected but associated with excellent outcomes**
S. Battistella, L. Turco, MC. Morelli, G. Frassanito, N. De Maria, L. Pasulo, S. Fagiuoli, C. Di Benedetto, MF. Donato, B. Magro, D. Pagano, S. Bhoori, V. Mazzaferro, A. Lauterio, L. De Carlis, D. Forastiere, M. Rendina, D. Angrisani, A. Galeota Lanza, G. Scandali, G. Svegliati Baroni, S. Piano, P. Angeli, C. Manuli, S. Martini, P. De Simone, P.G. Vacca, D. Ghinolfi, R. Lionetti, V. Giannelli, L. Mameli, E. Fornasiere, P. Toniutto, M. Biolato, FR. Ponziani, I. Lenci, A. Ferrarese, N. Passigato, S. Marenco, E. Giannini, F. Ferri, S. Trapani, P. Grossi, A. Aghemo, A. Zanetto, FP. Russo, P. Burra

33 **Hepatitis D and liver transplantation over two decades: Younger recipients, more decompensated disease, but superior post-transplant survival. A study from the ELTR (European Liver Transplant Registry)**
G. Germani, M. Buti, G. Papatheoriditis, P. Lampertico, R. Adam, V. Karam, S. Alqahtani, M. Papatheodoridi, M. Stepanova, P. Burra, Z. Younossi

72 **Excellent long-term survival and low viral recurrence after liver transplantation for HBV/HDV coinfection**
S. Iacob, M. Chitul, R. Cerban, C. Este, M. Ghioca, R. Iacob, C. Gheorghe, M. Grasu, I. Lupescu, D. Hrehoret, V. Brasoveanu, I. Popescu, L. Gheorghe

AI-based approaches for liver diseases: lessons learned

19 **Synthetic data generation by artificial intelligence predicts clinical outcomes in untreated and Bulevirtide-treated patients with chronic hepatitis delta**
S. D'Amico, E. Degasperi, S. de Nicola, N. Pugliese, MP. Anolli, M. Borghi, S. Baccino, I. Ferrari, D. Roulot, M. Della Porta, A. Aghemo, P. Lampertico

27 **Artifical intellingence and synthetic data to investigate predictors of clinical outcomes in Bulevirtide-treated patients with chronic hepatitis delta**
E. Degasperi, S. Baccino, S. D'Amico, S. de Nicola, N. Pugliese, MP. Anoll, M. Borghi, I. Ferrari, M. Della Porta, A. Aghemo, P. Lampertico